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1. Introduction 
Established tumor-derived cell lines are widely and routinely used as in vitro cancer models 
for various kinds of biomedical research. The easy management of these cell cultures, in 
contrast to the inherent difficulty in establishing and mantaining primary tumoral cultures, 
has contributed to the wide use of these inmortalized cell lines in order to characterize the 
biological significance of specific genomic aberrations identified in primary tumors. 
Therefore, it has been assumed that the genomic and expression aberrations of long-term 
established cell lines resemble, and are representative, of the primary tumor from which the 
cell line was derived. Indeed, the cell line-based research has been performed, not only for 
the definition of the molecular biology of several cancer models, but also for the 
investigation of new targeted therapeutic agents in a prior step to clinical practice. The use 
of tumor-derived cell lines has been highly relevant for the testing and development of new 
therapeutical agents, with several cancer cell-line panels having been developed for drug 
sensitivity screening and new agents’ discovery (Sharma et al, 2010).  
Controversial concerning the ability of tumor-derived cell lines to accurately reflect the 
phenotype and genotype of the parental histology has been documented. A previous report 
of Greshock and coworkers using array-based Comparative Genomic Hybridization (aCGH) 
data of seven diagnosis-specific matched tumors and cell lines showed that, on average, cell 
lines preserve in vitro the genetic aberrations that are unique to the parent histology from 
which they were derived, while acquiring additional locus-specific alterations in long-term 
cultures (Greshock et al, 2007). In contrast, a study on breast cancer cell lines and primary 
tumors highlight that cell lines do not always represent the genotypes of parental tumor 
tissues (Tsuji et al, 2010). Furthermore, a parallel genomic and expression study on glioma 
cell lines and primary tumors states that in this specific cancer type, cell lines are poor 
representative of the primary tumors (Li et al, 2008). Given the importance of the use of cell 
lines as models for the study of the biology and development of tumors, and for the testing 
of the mode of action of new therapeutical agents, the knowledge of which genomic 
alterations are tumor-specific or which are necessary for the maintenance of the cell line in 
culture, becomes essential. 
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Sometimes cell line studies are interpreted in the context of artifacts introduced by selection 
and establishment of cell lines in vitro, given the prevalence of documented cell line-specific 
cytogenetic changes acquired with multiple growth passages which is associated with random 
genomic instability. Therefore, the ability of glioma cell-line models to accurately reflect the 
phenotype and genotype of the parental glioma tumors remains unstudied. The aim of this 
study is to compare the genomic aberrations of the most commonly used glioma cell lines for 
in vitro analysis with those alterations more prevalent in primary glioma tumors.  
2. Copy number alterations in glioma cell lines 
2.1 High-level DNA copy number alterations in glioma cell lines 
2.1.1 Amplifications 
Genomic high-level DNA copy number gains (regions of amplification, or amplicons, i.e. 
chromosome regions that show more than 5- to 10-fold copy number increases) were 
detected at 4q, 10q and 19q in two of the cell lines: SW1783 (4q12) and SF767 (10q21.2-q23.1 
and 19p12) (table 1, figure 1). The MLPA analysis confirmed some of the genomic alterations 
observed by aCGH, such as the amplification of PDGFRA (4q12) which was observed in 
SW1783 cell line (see below table 3). 
 
CHROMOSOME GENES
CELL LINE (Region
Size Mb)
4q12
CHIC2, GSH2, PDGFRA, KIT, KDR, SRD5A2L, TMEM165, CLOCK, PDCL2, 
NMU, EXOC1, CEP135, AASDH, PPAT, PAICS, SRP72, HOP, SPINK2, REST, 
OLR2B, IGFBP7
SW1783 (3.57)
10q21.2 - q23.1
COL13A1, H2AFY2, AIFM2, TYSND1, SAR1A, PPA1, NPFFR1, LRRC20, 
EIF4EBP2, NODAL, PRF1, ADAMTS14, SGPL1, PCBD1, UNC5B, SLC29A3, 
CDH23, PSAP, CHST3, SPOCK2, ASCC1, DNAJB12, CBARA1, CCDC109A, 
OIT3, PLA2G12B, P4HA1, NUDT13, ECD, DNAJC9, MRPS16, TTC18, 
ANXA7, ZMYND17, PPP3CB,  , USP54, MYOZ1, SYNPO2L, SEC24C, FUT11, 
NDST2, CAMK2G, PLAU, VCL, AP3M1, ADK, MYST4, DUSP13, SAMD8, 
VDAC2, KCNMA1, DLG5, NAG13, POLR3A, RPS24, ZMIZ1, PPIF, SFTPD, 
ANXA11, MAT1A, DYDC1, DYDC2, TSPAN14, NRG3
SF767 (13.37)
19p12 ZNF43,SINE-R ,ZNF208,ZNF257 SF767 (0.28)
 
Table 1. Summary of high-level gains (amplifications) detected by aCGH 
Amplification of the EGFR gene, located on chromosome 7, and subsequent over-expression 
of EGFR protein, is the most common genetic alteration found in primary glioblastoma 
(GBM), the most aggressive high-grade glioma. This amplification is detected in about 40% 
of these tumors, and is present as double-minute extrachromosomal elements (Louis et al, 
2007). Amplification of the EGFR gene is often associated with structural rearrangements, 
resulting in tumors expressing both wild-type EGFR as well as the mutated EGFR. The most 
common truncated EGFR variant is the EGFRvIII one, consisting of 801-bp in-frame deletion 
comprising exons 2-7 of the gene.  
Among the cell lines analyzed in this study, some of them derived from primary GBMs, 
none of them carried either amplification of the EGFR gene, nor the EGFRvIII mutant form 
of the receptor (Figure 2). Besides, EGFR sequence analysis of exons 18-21, coding for the 
tyrosine kinase domain, revealed not a mutation in this region, unlike what is found in non-
small lung cancer tumors. 
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Fig. 1. aCGH results of chromosomes 4 (a) and 10 (b) in SW1783 and SF767 cell lines, 
respectively. Moving average of log2-genomic ratios over five neighbouring genes are 
plotted. 
 
Fig. 2. RT-PCR analysis for the detection of EGFR wild-type (EGFRwt) and EGFRvIII mutant 
receptor. The inset shows control gene GAPDH results. Line 1: GOS3, 2: A172, 3: U118, 4: 
SF767, 5: T98, 6: wt EGFR control, 7: EGFRvIII control; M: molecular marker. 
2.1.2 Homozygous deletions 
Analysis of the high-level copy number changes detected by aCGH in the eleven glioma cell 
lines revealed higher frequency of genomic losses than gains. A stringent filter was applied 
in order to detect homozygous deletions. 
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Genomic homozygous losses were detected at 1p, 1q, 2q, 3p, 4q, 5q, 6q, 7p, 9p, 10p, 10q and 
21p (Table 2).  
Homozygous losses affecting two or more cell lines were detected at 1p33, 9p21.3-21.1, 
10q23.2-23.3 and 21p11.1 (Table 2). Main target genes of these regions were: CDKN2C 
(p18INK4c) on chromosome 1, CDKN2A (p16INK4a) and CDKN2B (p15INK4b) on chromosome 9, 
and PTEN on chromosome 10. The most frequent homozygous gene loss was the loss of 
CDKN2A (p16INK4a) and CDKN2B (p15INK4b), affecting nine (82%) and eight (73%) of 11 
glioma cell lines, respectively.  
2.1.2.1 Loss of CDKN2C 
The Cancer Cell Line project (CCL) database from the Genome Cancer Project of the Sanger 
Institute (http://www.sanger.ac.uk/genetics/CGP/CellLines/) was used to confirm these 
alterations when possible. Homozygous deletion of CDKN2C (1p33) was described in this 
project for T98 and U87 cell lines. Homozygous deletion of CDKN2C on U373 cell line was 
not reported in this project. By contrast, this deletion was not reported in the study of Li and 
coworkers for T98 and U87 cell lines (Li et al, 2008). 
2.1.2.2 Loss of CDKN2A and CDKN2B 
CDKN2A (9p21.3) loss of cell lines A172, H4, SW1088, T98, U118 and U87 was reported by 
the CCL project. Similarly, this gene was described as not mutated in SW1783, therefore 
confirming our results. Data from GOS3, LN18 and U373 were not provided in this 
database. Deletion of the 9p21 region was also reported in A172 and U87 cell lines by Li and 
coworkers, again validating our findings. Strikingly, T98 cell line was not deleted in that 
study (Li et al, 2008). Furthermore, the MLPA analyses performed on the cell lines 
confirmed the homozygous deletions observed by aCGH (Table 2). Therefore homozygous 
deletion of the CDKN2A gene was present in 9 of the 11 glioma cell lines (Table 2, Figure 3).  
Remarkably, there were two cell lines that lack any alteration at the CDNK2A locus, either 
by homozygous or hemizygous loss of the region. 
2.1.2.3 Loss of PTEN 
The aCGH analysis revealed homozygous deletion of PTEN in SW1088 and H4 cell lines 
(Table 2), which was confirmed by the MLPA assay (Figure 4). In addition, homozygous 
deletion of PTEN in these cell lines was also reported by the CCL project. PTEN hemizygous 
deletion was detected in SF767 and GOS3 cell lines by aCGH and MLPA. Surprisingly, A172 
cell line had homozygous deletion of all the PTEN probes of the MLPA assay except those of 
exons 1 and 2. This loss could not be detected by the aCGH analysis, probably because only 
two of the three probes included in the microarray were in the deleted part of PTEN 
(homozygous losses were considered as present when three consecutive clones were under 
the threshold 1.0) (Figure 4).  
Further analyses of PTEN sequence were performed attending to PTEN expression (see 
Table 5 in section 3). Western-blot analysis showed PTEN expression in T98, LN18, GOS3 
and SF767 (the two latter carring hemizygous deletion of the gene). Lack of protein 
expression was found in 7 of the eleven cell lines, three of them having homozygous 
deletion of PTEN. Therefore, we carried out exon-sequencing analysis of the other four 
PTEN deficient cell lines (U118, U87, U373 and SW1783) in order to detect putative 
mutations of the genomic sequence that could explain the observed suppression of protein 
expression. U118 and U87 presented a substitution mutation (G>T) in the splicing site of 
exons 8 (c.1026+1G>T) and 3 (c.209+1G>T), respectively; U373 showed an homozygous TT 
insertion in exon 7 causing a shift in the reading frame (c.723_724insTT); and SW1783 
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showed a substitution in exon 7 (c.691C>T) which results in a stop codon (CGA>TGA). The 
latter mutation was confirmed with the database from the Cancer Genome Project (CGP, 
Sanger Institute). The CGP report the same mutation that we found in cell line U373, for the 
U251 glioma cell line, which is derived from the same tumour as U373, and thus contains 
the same TT insertion mutation in PTEN. 
 
CHROMOSOME GENES CELL LINE (Mb lost)
1p33 FAF1, CDKN2C U87 (0.17), T98 (0.07), U373 (0.23)
1p31.1
LRRC44, FPGT, TNNI3K, 
CRYZ, TYW3
U118
1q42.2 DISC1,SIPA1L2,PCNXL2 GOS3 (1.33)
2q42.2 BAZ2B GOS3 (0.12)
3p24.3
TBC1D5,SATB1,KCNH8,
EFHB,RAB5A, SGOL1, PCAF
H4 (4.63)
3p24.1 TGFBR2 SF767 (0.23)
3p12.2-p11.2
IGSF4D,VGLL3,CHMP2B,
POU1F1,HTR1F, CGGBP1
LN18 (6.32)
4q34.1 FBXO8,HPGD,GLRA3 U118 (0.40)
5q14.1 THBS4, SERINC5 SF767 (0.13)
6q22.2 ROS1,DCBLD1 U118 (0.17)
7p21.2-p21.1
ETV1, DGKB, MEOX2, OSTDC1, 
ANKMY2, BZW2, TSPAN13, 
AGR2, BCMP11, AHR, SNX13, 
HDAC9
SF767 (5.09)
9p22.1-p21.1 SLC24A2 LN18 (6.37)
MLLT3, IFNB1 U118 (10.86), U87 (3.52), LN18
IFNW1 U118, U87,LN18, H4 (1.22)
KLHL9,IFNA2,IFNA8 U118, U87,LN18, H4, SW1088 (7.22)
IFNE1,MTAP U118, U87,LN18, H4, SW1088,A172 (0.71)
9p21.3-p21.1 CDKN2A U118,U87,LN18,H4,SW1088,T98,U373,A172,GOS3 (0.18)
CDKN2B U118, U87,LN18, H4, SW1088, U373, A172, GOS3
ELAVL2 U118, LN18, SW1088
hel-N1 U118, LN18
PLAA, IFT74,  LNG01784, TEK, 
MOBKL2B, LRRN6C
U118, SW1088
LINGO2 U118
10p11.21 PARD3 T98 (0.11)
MINPP1 H4 (0.73)
10q23.2 - q23.31 PAPSS2,ATAD1,PTEN H4,SW1088
LIPF,ANKRD22,STAMBPL1, 
ACTA2, FAS,CH25H,LIPA
SW1088 (1.50)
10q25.2 TCF7L2 T98 (0.16)
12q21.2 PAWR GOS3 (0.14)
21p11.1
BAGE4,BAGE5,BAGE3,BAGE2, 
BAGE
H4 A172, U118, GOS3 (0.04)
 
 
Table 2. Homozygous losses detected in glioma cell lines by aCGH 
www.intechopen.com
 
Glioma – Exploring Its Biology and Practical Relevance 
 
434 
 
 
 
 
 
U118
0
5
5
CDKN2A EGFR ERRB2 PTEN P53
CHROMOSOME 9
0.5
0
-0.5
-1.0
-1.5
1.5
1.0
0.5
0
a)
 
 
 
 
www.intechopen.com
 
Copy Number Alterations in Glioma Cell Lines 
 
435 
 
 
 
 
CDKN2A EGFR ERRB2 PTEN P53
0.5
0
-0.5
-1.0
-1.5
1.0
0.5
0
CHROMOSOME 9
b)
 
 
 
 
Fig. 3. Homozygous loss detected on chromosome 9 (including CDKN2Alocus) in two 
representative cell lines: U118 (a) and LN18 (b). Upper panel: aCGH plot (moving average of 
log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
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Fig. 4. Homozygous loss detected on chromosome 10 (including PTEN) in two 
representative cell lines: SW1088 (a) and H4 (b). Upper panel: aCGH plot (moving average 
of log2-genomic ratios over five neighbouring genes); Lower panel: MLPA graph (each bar 
represents a probe of the MLPA assay). 
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2.2 Low-level DNA copy number alterations in glioma cell lines 
Analyses of the DNA copy number changes in 11 of the most commonly used glioma cell 
lines revealed higher frecquency of genomic losses than gains. While 22.15% of the analyzed 
probes were lost, only 12.35% of them presented gains. Chromosomes containing frequently 
gained probes among all the cell lines included chromosomes 7, 16, 17, 19 and 20. Similarly, 
chromosomes containing frequently lost probes included chromosomes 4, 6, 10, 13, 14 and 
18 (Figure 5). Surprisingly, chromosome 9, presenting loss of the CDKN2A/CDKN2B locus 
in most of the cell lines (9 out of 11 cell lines) presented a similar percentage of gained and 
loss probes. This result may be explained due to this loss is relatively small in most of the 
cell lines, and to the low-level DNA copy number gain of most of chromosome 9 in SF767 
cell line (data not shown). 
 
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
C
h
r.
1
c
h
r2
c
h
r3
c
h
r4
c
h
r5
c
h
r6
c
h
r7
c
h
r8
c
h
r9
c
h
r1
0
c
h
r1
1
c
h
r1
2
c
h
r1
3
c
h
r1
4
c
h
r1
5
c
h
r1
6
c
h
r1
7
c
h
r1
8
c
h
r1
9
c
h
r2
0
c
h
r2
1
c
h
r2
2
 
Fig. 5. Percentage of low-level DNA copy number gains (black) and losses (grey) relative to 
the analyzed probes in the microarray per chromosome. 
Chromosome 7 was one of the most gained chromosomes, with complete or almost 
complete chromosome 7 gain in SW1088 and GOS3 cell lines, or with relative wide regions 
of gain in H4, U373, U118 or A172 cell lines. Gain of the EGFR gene (located at 7p12) was 
evaluated by MLPA assays, showing EGFR low-level copy number gain in 8 out of the 11 
cell lines (table 3).  
Other gains detected by MLPA analysis were PI3KCA, BRAF and BIRC5. Three of the cell 
lines presented a PI3KCA gain (3q). PIK3CA is one of the three genes encoding components 
of PI3K which is involved in activation of AKT signaling. Amplification of PIK3CA has been 
observed in various types of cancer, including gliomas (Karakas, 2006; Kita, 2007; Vogt, 
2006). BRAF oncogene (7q34) was gained in five of the cell lines. BRAF is a serine/threonine 
kinase that is frequently activated in many types of cancer by a specific mutation (V600E). In 
pilocytic astrocytomas, BRAF is frequently activated by tandem duplication and 
rearrangement of part of the gene, resulting in fusion proteins containing the kinase domain 
(exons 9-18). Activation of BRAF through these mechanisms of duplication or fusion is 
infrequent in diffusely infiltrating astrocytic gliomas (Bar et al, 2008; Riemenscheneider et al, 
2010). All the cell lines analyzed in this study were obtained from adult patients with high 
grade gliomas.  
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BIRC5 or survivin (17q) was gained in five of the cell lines. Survivin, which promotes cell 
proliferation, angiogenes and inhibits apoptosis, is frequently overexpressed in proliferating 
tissues and tumors (Zhen et al, 2005). In gliomas, survivin overexpression is significantly 
associated with tumorigenesis and progression, and with a worse prognosis of patients 
(Shirai et al, 2009). Previous studies revealed, as well, BIRC5 gain and overexpression in 
oligodendroglial tumors (Blesa et al, 2009). High expression of BIRC5 in nervous system 
tumors have been already reported (Das, 2002; Hogdson, 2009; Sasaki, 2002).  
As a summary, at the gene-level, the most represented gains and losses in the 11 analyzed 
cell lines are shown in table 4. 
 
 CHROMOSOME GENE NAME CELL LINE 
HOM 
LOSS 
9p21 CDKN2A 
U373, U118, SW1088, GOS3, A172, H4, T98, 
U87, LN18
10q23 PTEN A172, SW1088, H4
HEMI 
LOSS 
1p13.2 NRAS A172, H4
10q23 PTEN SF767, GOS3
GAIN 
1p13.2 NRAS U373
1q32 PI3KC2B A172
2q35 IGFBP2 SW1088
3q26.3 PIK3CA A172, SW1783, H4
7p12 EGFR 
U373, U118, SW1088, GOS3, A172, H4, T98, 
SF767
7q34 BRAF U87, U373, SW1088, GOS3, T98
17p11.2 TOM1L2 LN18
17q25 BIRC5 H4, LN18, T98, U373, SW1783
21q22.3 RUNX1 H4, A172, T98
A 4q11 PDGFRA SW1783
Table 3. Summary of gene-specific MLPA-validated copy number alterations (HOM LOSS: 
homozygous loss; HEMI LOSS: one copy loss; GAIN: low-level copy number gains; A: 
amplifications). 
 
GAIN HOMOZYGOUS DELETION 
Gene (location) Total Gene (location) Total 
EGFR (7p12) 8 CDKN2A (9p21) 9 
BRAF (7q34) 5 CDKN2B (9p21) 8 
BIRC5 (17q25) 5 MTAP (& others; 9p21) 6 
PI3KCA (3q26.3) 3 BAGE (21p11.1) 4 
 PTEN (10q23) 3 
CDKN2C (1p33) 3 
Table 4. Summary of the alterations most represented on the eleven glioma cell lines 
studied. (Total: number of cell lines presenting the alteration described) 
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Fig. 6. Genomic analysis of A172 (a, b) and SW1088 cell lines (c, d). a) MLPA analysis (each 
bar represents a probe of the MLPA assay) showing EGFR gain, CDKN2A homozygous 
deletion, and PTEN homozygous deletions except for exons 1 and 2. b) aCGH analysis 
(moving average of log2-genomic ratios over five neighbouring genes) of chromosomes 7, 9 
and 10. c) MLPA analysis showing EGFR gain, and homozygous deletions of CDKN2A and 
PTEN d) aCGH analysis of chromosomes 7, 9 and 10. Observe that no PTEN deletions 
(10q23.2) were detected in A172 cell line compared to SW1088. 
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3. Comparison between copy number alterations in glioma cell lines and 
primary tumors 
Gliomas are the most frequent primary brain tumors, and include a variety of different 
histological tumor types and malignancy grades. High-grade gliomas are those graded as III 
or IV according to the criteria of the World Health Organization (WHO) classification 
system (Louis et al, 2007), including anaplasic astrocytoma (WHO grade III) and GBM 
(WHO grade IV). High-grade gliomas may arise from diffuse astrocytoma WHO grade II or 
III, or de novo, i.e. without evidence of a less malignant precursor lesion. GBM is the most 
frequent primary brain tumor. Primary GBM manifest rapidly de novo, while secondary 
GBM develops slowly from diffuse or anaplastic astrocytomas. 
It is important to note that most of the cell lines used in this study derived from astrocytoma 
tumors of high-grade (8 cell lines: T98, LN18, U373, SW1088, H4, SW1783, U118, and A172), 
with the exception of GOS3 cell line that was derived from a high-grade mixed tumor with 
oligodendroglial component. 
From a genetic point of view, progression to malignancy in gliomas is a multistep process, 
driven by the sequential acquisition and accumulation of genetic alterations. Distinctions 
between the genetic alterations identified in primary and secondary GBM have been made, 
with TP53 mutations occurring more commonly in secondary GBMs and EGFR 
amplifications, and PTEN mutations occurring more frequently in primary GBMs. However, 
none of these alterations sufficiently distinguishes between primary and secondary GBM.  
Recently, a comprehensive sequencing and genomic copy number analysis of GBM tumors 
showed that the majority of the tumors analyzed had alterations in genes encoding 
components of each of the TP53, RB1, and PI3K pathways, previously known to be altered in 
GBMs (Parsons et al, 2008). In these tumors, all but one of the cancers with mutations in 
members of a pathway did not have alterations in other members of the same family, 
suggesting that such alterations are functionally equivalent in tumorigenesis. Opposite to 
what is found in primary and secondary GBMs, glioma cell lines usually harbor functional 
alterations of the three pathways simultaneously (e.g. SW1088, SW1783 or U118, table 5). 
Alteration mutations of the tumor suppressor gene TP53 (located at 17p13.1) and loss of 
heterozygosity on chromosome arm 17p are frequent in secondary GBM. While TP53 copy 
number analysis showed nor gains or losses in the cell lines tested, neither by CGH nor by 
MLPA, point mutations have been reported by the Sanger database in some of the analyzed 
cell lines (Table 5). 
Primary GBM, on another hand, characterises by EGFR amplification or overexpression, 
PTEN mutation, trisomy of chromosome 7, monosomy of 10 and genomic gains of 12p, 19q 
and 20q (Riemenschneider et al, 2010).  
Regarding alterations of PTEN gen (PI3K pathway), loss of chromosome 10 is one of the 
most frequent alteration in primary GBM tumors (60-80% of cases). While many tumors 
show loss of one entire copy of chromosome 10, loss of heterozygosity (LOH) studies have 
reported the involvement of several regions of LOH, suggesting several potential tumor 
suppressor genes in addition to PTEN. The cell lines analyzed in our study frequently 
presented alteration of PTEN gene (nine out of 11 cell lines), either by mutation or genomic 
loss. Absence of PTEN protein expression in these cell lines was confirmed in seven of these 
cell lines by western blot (data not shown). 
Concerning amplifications, EGFR high-level copy number gain is the most frequent 
alteration found in primary GBM. As mentioned before, this alteration is present as double-
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minutes, i.e. small and circular fragments of extrachromosomal DNA that are replicated in 
the nucleus of the cell during cell division but that, unlike actual chromosomes, lack 
centromere or telomere. This EGFR amplification has not been detected in any of the 
analyzed glioma cell lines, probably due to the difficulty in maintaining a highly unstable 
extrachromosomal fragment that lacks centromere, in long-term cultures. A recent report, 
however, describes another type of EGFR gain in which extra copies (in small numbers) of 
EGFR are inserted in different loci of chromosome 7 (Lopez-Gines et al, 2010). The presence 
of this type of gain in glioma cell lines remains to be studied. 
 
RB  pathway
CDKN2A PTEN PTEN seq EGFR EGFRvIII Tp53 p53 mut
T98G del HOMO N - G No N p.M237I
LN18 del HOMO N - N No N* nd
SF767 N del HEMI - G No N* nd
U373 del HOMO N* c.723_724insTT G No N nd
U87MG del HOMO N* c.209+1G>T N No N* nd
SW1088 del HOMO del HOMO* - G No N p.R273C
H4 del HOMO del HOMO* - G No N* nd
SW1783 N N* c.691C>T N No N p.R273C
U118 del HOMO N* c.1026+1G>T G No N p.R213Q
GOS3 del HOMO del HEMI - G No N nd
A172 del HOMO del HOMO
*,#
- G No N* nd
PI3K  pathway TP53  pathway
 
*Protein expression not detected (Western-blot or Immunohistochemistry, data not shown) #deletion 
except for exons 1 and 2. del HOMO: homozygous deletion; del Hemi: hemizygous deletion; G: Gain; N: 
No copy number change; No: EGFRvIII mutation not detected; p53 mut: data from the Sanger database; 
nd: no data from available. 
Table 5. Alterations of the RB, TP53 and PI3K pathways. 
Thus, at least for what concerns to the EGFR amplification, glioma cell lines seem not to 
resemble primary tumors. This result contrast to what is found in breast cancer cell lines, 
where amplification of ERBB2 (17q12) is detected indeed more frequently in cell lines that in 
primary tumors (Tsuji et al, 2010). Of note, amplification of ERBB2 takes place within 
homogeneously staining regions, where the extra copies of the gene are integrated within 
the chromosome, thus allowing its maintenance in established cell lines. 
Similarly, other amplifications reported in primary GBM tumors have not been found in 
these cell lines, such as those of 1q (MDM4, PIK3C2B), 7q (MET, PEX1, CDK6), 12p (CCDN2) 
12q (MDM2, GLI, CDK4) or 13q (Rao et al, 2010; Ruano et al, 2006). The only common 
amplification detected in glioma cell lines and tumors was that of 4q (PDGFRA) which was 
detected in SW1783 cell line. PDGFRA encodes for a cell surface tyrosine kinase receptor of 
the members of the platelet-derived growth factor family. These growth factors are mitogens 
for cells of mesenchymal origin and activate intracellular signaling through the MAPK, PI3K 
and PKCgamma pathways with roles in the regulation of many biological processes 
including embryonic development, angiogenesis, cell proliferation and differentiation. On 
the other hand, to our knowledge, amplifications of 10q and 19p detected in SF767 cell line 
have not been reported before in glioma tumors.  
Digital karyotyping for eight tumor-derived cultured samples and one bulk tumor was used 
by Rao and coworkers (2010) to describe genomic alterations in GBM. This group described 
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amplifications in 1q, 7p, 8q and 12q, and homozygous deletions in 1p, 9p and 9q. However 
7p11.2-12.1 (EGFR), 8q24.21 (MYC) and 12q15 (MDM2) amplifications were found just in 
case of the tumor sample, consistent with previous observations that adherent GBM cells 
tend to lose EGFR amplification during culturing. The most frequent amplifications found 
by this group was 12q13.3-q14.1, which targeted GLI1 and CDK4 oncogenes, affecting 3 
samples. Two of the samples showed amplification of PI3KC2B and MDM4 in 1q32.1. Table 
6 shows comparison of our results with those published by Rao and coworkers (2010). Low-
level copy number gains (e.g. PI3KC2B: A172 cell lines; EGFR: 8/11 cell lines) but not 
amplifications were detected in the cell lines. 
The p16ink4a/CDK4/RB1 pathway is important for the control of progression through G1 
into the S phase of the cell cycle. In GBM tumors, alterations affecting this pathway are 
found at an overall frequency of 40-50% (Louis et al, 2007). Homozygous deletions affecting 
CDKN2A locus (9p21) were described by digital karyotyping in 44% of cultured samples 
(four out of nine) (Rao et al, 2010). Our study reveals 82% (9/11) and 73% (8/11) of cell lines 
carrying homozygous deletions for CDKN2A and CDKN2B genes, respectively (Table 6).  
 
Chromosome band Target oncogene Rao % 
(n=9) 
Our group % 
(n=11) 
Amplifications/Gains (G) 
1q32.1 
1q32.1 
PIK3C2B 
MDM4 
22 
22 
9 (G) 
0 
7p11.2-12.1 EGFR 11 73 (G) 
8q24.21 MYC 11 45 (G) 
12q13.3-q14.1 GLI1,CD4 33 18 (G) 
12q14.1 Unknown 22 9 (G) 
12q15 MDM2 11 0 
Homozygous deletions 
1p36.31-p36.23 TP73, LRRC47, DFFB 33 18 
9p21.3-22.3 CDKN2A, CDKN2B 44 82, 73 
9q34.3 CACNA1B 44 0 
Table 6. Comparison of results obtained by Digital Karyotyping (Rao et al, 2010) with aCGH 
alterations observed in glioma cell lines. Only amplification data from Rao´s study was 
available.  
Finally, regarding the number of DNA copy number alterations in cell lines, the lost probes 
almost doubled the gained ones, with an average of losses and gains per cell line of 9,908 
and 5,072 probes, respectively. This result contrast to what is observed in primary GBM 
tumors, having similar numbers of gains and losses (Ruano et al, 2006). Accordingly, similar 
results were obtained in tumor-derived cell lines from other histologies (Greshock et al, 
2007) and specifically in breast cancer cell lines (Tsuji et al, 2010; Naylor et al, 2005), with 
more alterations found in cell lines than in tissue specimens, as a general trend. In fact, 
genomic losses in breast cancer cell lines almost doubled the gains (Tsuji et al, 2010). These 
observations may suggest the accumulation of genomic alterations in long-term cultures 
that are not present in primary tissues. 
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4. Cell culture specific aberrations 
Several of the frequent genomic alterations detected in glioma cell lines are not found in 
primary tumors, suggesting that some of the commonly seen alterations in vitro could be 
artifacts secondary to the selection pressure for optimal cell growth in vitro following years 
of passage. This observation has been reported previously in gliomas (Li et al, 2008), but the 
presence of acquired locus-specific alterations in culture has also been recognized in tumors 
and cell lines of other histologies (Greshock et al, 2007). For example, genome-specific copy 
number alterations of chromosomes 5 (gained), 8, 11 and 18 (lost) in glioma cell lines have 
been attributed exclusively to the phenotype of established cell lines. Furthermore, other 
copy number alterations not commonly found in cell lines, such as those of specific areas of 
chromosomes 2, 3, 6 and 8 have been rarely observed in primary tumors. 
Our findings (Figure 5) have identified areas of low-level gain on chromosomes 5, 16 and 17 
affecting between 5 and 7 cell lines, which do not feature GBM tumors. In addition, areas of 
loss of chromosomes 6, 8, 11, and, most importantly, loss of chromosome 18 have been 
identified in most of cell lines. These alterations seem to be culture-associated changes 
present in cell lines and suggest a genomic instability phenotype in established cell lines that 
is not present in primary tumor tissues. 
Absence of chromosome 13 deletions in glioma cell lines, which were commonly found in 
primary GBMs, was reported by Li and coworkers (2008) as a striking discrepancy between 
cell lines and tumors. Our study, however, did detected chromosome 13 losses (Figure 5). In 
the present study, complete loss of chromosome 13 was identified by aCGH in H4, LN18, 
U373, SW1088 and U118 cell lines, while partial loss was detected in U87, SF767, SW1783 
and A172 cell lines. No loss was observed in T98 and GOS3 cell lines. Curiously, cell lines 
analyzed in common by our study and that of Li, had partial chromosome 13 loss in our 
study and partial chromosome 13 LOH in the study of Li and coworkers (U87 and A172), or 
no chosmosome 13 loss in both studies (T98). 
5. Material and methods  
5.1 Cell lines and cell culture  
The human glioma cell lines GOS3, U87MG (U87), A172, SW1783, U118 MG (U118), T98G 
(T98), SW1088, H4, LN18, U373MG (U373) and SF767WL (SF767) were kindly provided by 
Dr. Velasco (Complutense University of Madrid, Spain) or Dr. Setién (Catalan Institute of 
Oncology, Spain). These cell lines were maintained in RPMI medium containing 10% FBS 
(Gibco, Grand Island, NY) in standard culture conditions. Total DNA and RNA were 
extracted from cell cultures according to standard phenol-chloroform and Trizol (Invitrogen, 
Carlsbad, CA) techniques, respectively. Nucleic acids obtained were quantified using 
NanoDrop-1000 (NanoDrop Technologies, Inc., Wilmington, DE). 
5.2 Comparative genomic hybridization  
Copy number analyses of the 11 glioma cell lines were screened by array-based 
Comparative Genomic Hybridization (aCGH) in the Microarrays Analysis Service of the 
CIPF (Centro de Investigación Principe Felipe, Valencia). “Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis” protocol Version 4.0 (Agilent Technologies, Palo 
Alto, California USA. p/n G4410-90010) was followed to obtain labeled DNA. 2000 ng of 
DNA from samples and reference DNA (pool of sex-matched normal brain DNA) was 
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fragmented and labeled (Cyanine 3-dUTP for the cell lines DNA and cyanine 5-dUTP for the 
reference DNA) according to the “Agilent Genomic DNA labeling kit plus” protocol. 
Labeled DNA was hybridized with Human Genome CGH Microarray 44 k (Agilent p/n 
G4426B-014950) containing 45,214 probes with 42,494 distinct biological features. Arrays 
were scanned in an Agilent Microarray Scanner (Agilent G2565BA). Data was analyzed 
using DNA Analytics 4.0 CGH Module (Agilent Technologies). Genomic alterations were 
detected using an ADM-2 algorithm with two different filters: one, used to detect low level 
alterations, , detects those alterations affecting to three consecutive probes with a ratio above 
or below to 0.25; the other, used to obtain amplifications or homozygous deletion, included 
in 2.1 section, detects only three consecutive probes above or below a ratio of 1.0.  
5.3 MLPA analysis 
Specific gene alterations were validated by Multiple ligation probe assay experiments 
(MLPA®, Mrc-Holland, The Netherlands) with SALSA MLPA kit P105 Glioma-2 for EGFR, 
PTEN, CDKN2A and p53. Besides, SALSA® MLPA® kit P173 was used to detect copy 
number alteration of several genes which are frequently altered in several tumors, such as: 
BCL2L11, BIRC5, BRAF, ERBB4, JAK2, NRAS, PDGFRA, PIK3C2B, PIK3CA. MLPA assays 
were carried in total DNA from the eleven cell lines, obtained by standard methods, 
following manufacturers’ conditions. Polymerase chain reaction products were separated 
and quantified on an ABI PRISM 310 DNA sequencer (Applied Biosystems), and 
electropherograms were analyzed using GeneMapper v.3.7 software (Applied Biosystems). 
Three nontumor reference samples were included in each run. 
5.4 EGFRvIII analysis 
Presence of EGFR vIII variant was determined by RT-PCR from total RNA of the cell 
cultures. cDNA was obtained from lµg of total RNA using the Superscript System (Gibco®). 
Primers and PCR conditions used were previously described (Lee et al, 2006). 
Amplifications products were visualized in bromure ethydium 2% agarose gel. 
5.5 EGFR and PTEN sequence analysis  
Mutations in exons 1 to 9 of PTEN gene and 18 to 21 of the EGFR gene were screened by 
direct sequencing in an ABI PRISM 310 DNA Analyser (Applied Biosystems) according to 
the manufacturer’s instructions. PCR primers and conditions for EGFR amplification were 
previously described (Hsieh et al, 2006). 
 
Exon Upstream primer 5'-3' Downstream primer 5'-3' Annealing T (°C)
1 TCCTCCTTTTTCTTCAGCCAC GAAAGGTAAAGAGGAGCAGCC 56
2 GCTGCATATTTCAATCAAACTAA ACATCAATATTTGAAATAGAAAATC 54
3 TGTTAATGGTGGCTTTTTG GCAAGCATACAAATAAGAAAAC 56
4 TTCCTAAGTGCAAAAGATAAC TACAGTCTATCGGGTTTAAGT 56
5 TTTTTTTTTCTTATTCTGAGGTTAT GAAGAGGAAAGGAAAAACATC 51
6 AGTGAAATAACTATAATGGAACA GAAGGATGAGAATTTCAAGC 54
7 AATACTGGTATGTATTTAACCAT TCTCCCAATGAAAGTAAAGTA 56
8 TTTTTAGGACAAAATGTTTCAC CCCACAAAATGTTTAATTTAAC 54
9 GTTTTCATTTTAAATTTTCTTTC TGGTGTTTTATCCCTCTTG 54  
Table 7. PTEN sequence and annealing temperature used for PCR reactions of nine exon 
primers 
www.intechopen.com
 
Copy Number Alterations in Glioma Cell Lines 
 
445 
6. Conclusion  
High-level copy number alterations have been observed in cell lines of different sources 
such as breast, melanoma or lung tumors. Some authors suggest that some of the commonly 
seen alterations in the glioma cell lines can be due to the in vitro cell growth process 
following long term passage cultures. These observations are based on (i) the comparison of 
the genomic alterations of glioma and other non glioma cancer cell lines: some of these 
alterations are common between established cancer cell lines from different origin and 
uncommon in glioma tumors (Li et al, 2008). ii) Differential expression analyses suggest that 
established cancer cell lines share an underlying molecular similarity more closely related to 
their in vitro culture conditions than to their original tumor type of origin. Although some 
functional signalling pathways are up-regulated both in glioma tumors and glioma cell lines 
(epidermal growth factor receptor, vascular endothelial growth factor receptor, p53, PI3K 
pathway), there are some others gene expression sets whose up-regulation is just seen in 
cancer cell lines (cell cycle, proteasome activity, purine metabolism, mitochondrial activity). 
Our findings show that established glioma cell lines and glioma tumours have differences in 
genomic alterations, concluding that glioma cell lines may not be such an accurate 
representation or model system for primary gliomas as would be desirable. As opposed to 
primary tumors, glioma cell lines did not present either EGFR amplification, or presence of 
EGFRvIII variant, events that are frequent in high-grade gliomas. Homozygous CDKN2A 
deletion was frequently observed in glioma cell lines, as occur in cell lines derived from 
other histologies and in glioma tumors. Chromosome 7 gain and PTEN deletions represent 
the most specific glioma alterations present in these cell lines. 
The easy of management of glioma cell lines make these cell lines as good candidate models 
for exploring basic glioma biology and for the use and discovery of therapeutic agents in 
preclinical screens. However, it is of interest that cell clycle-related alterations of gene 
expression are importantly affected in these cell lines, and that most drugs have been tested 
for cytotoxicity against rapidly dividing cells. Therefore, selection bias toward the 
identification of therapeutic agents involved in molecular functions more related to the long 
term culture than to glioma biology could occur. 
On the other hand, many efforts are being done to create adequate culture conditions that 
allow the maintenance of the genomic profiles of the original tumor, such as glioma stem-
like cell cultures, which may be more representative of their parent tumors. Several reports 
have demonstrated that glioma cultures under serum free conditions and stimulated with 
mitogens, epidermal growth factor and fibroblast growth factor, grow as neurospheres and 
maintain a phenotype and genotype closer to that typical of primary tumours compared to 
traditional serum-derived cell lines and culture techniques (Fael Al-Mayhani et al, 2009; 
Ernst et al, 2009). Perhaps, the standardization of this culture method could enhance and 
improve the research with cell lines in brain tumors.  
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